Trinity Capital announced the commitment of up to $50 million in growth funding to Nalu Medical, Inc. ("Nalu"), a commercial-stage medical device company focused on developing and commercializing neurostimulation solutions for patients with chronic intractable neuropathic pain.   

Nalu is focused on creating solutions for chronic neuropathic pain through its proprietary implantable pulse generator (IPG) device. The company's Neurostimulation System features a small, non-integrated, implanted medical device that uses advanced electrical impulse waveforms to modulate pain signals before they reach the brain. Nalu's micro-IPG device is minimally invasive, battery-free, and can be controlled from the patient's smartphone. Nalu has been FDA-cleared for implantation and recently received FDA clearance for expanded labelling of its Peripheral Nerve Stimulation (PNS) therapy, now approved for whole-body MRI-conditional use.

"We are proud to partner with and support Nalu as they advance the care of patients with chronic neuropathic pain," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "We believe Nalu is a leader in PNS and is reshaping the pain management landscape through their innovative technology and robust clinical data."

"We welcome Trinity Capital as a financing partner and appreciate their confidence in providing us this important financial flexibility as we continue our commercial expansion of our newly launch, next-generation Therapy Disc, and build upon our recent publication of what we believe is the largest long-term real-world data set for a permanent PNS device that demonstrated reliable long-term pain relief to a broad spectrum of patients," said Tom West, President and CEO of Nalu.